

7. (amended) A pharmaceutical composition comprising a compound according to any one of claims 19, 21, 3, 4, or 5, [as claimed in any one of Claims 1 to 6] together with a pharmaceutically acceptable carrier therefore.

*dc 3*

10. (amended) A method for the treatment of a mammal, including man, suffering from or susceptible to viral infection comprising administration of an effective amount of a compound according to any one of claims 19, 21, 3, 4, or 5 [as claimed in any one of Claims 1 to 6].

*dc 4*

11. (amended) A method for the preparation of a compound according to claim 19, [as claimed in any one of Claims 1 to 6] which comprises the step of separating [separation of] the (-)-enantiomer from a mixture also containing the (+)-enantiomer.

*dc 5*

13. (amended) A method according to claim 11, wherein [as claimed in Claim 11 or 12] the separation is effected by chiral HPLC.

*dc 6*

15. (amended) A method according to claim 11, [as claimed in Claim 11 or Claim 12] wherein the separation is effected by enzyme-mediated enantioselective catabolism.

*dc 6*

16. (amended) A method according to [is claimed in] Claim 15 wherein the enzyme is employed in immobilized form.

Add claims 19-20.